Diphenhydramine Hydrochloride


Cardinal Health 107, Llc
Human Prescription Drug
NDC 55154-9363
Diphenhydramine Hydrochloride is a human prescription drug labeled by 'Cardinal Health 107, Llc'. National Drug Code (NDC) number for Diphenhydramine Hydrochloride is 55154-9363. This drug is available in dosage form of Injection, Solution. The names of the active, medicinal ingredients in Diphenhydramine Hydrochloride drug includes Diphenhydramine Hydrochloride - 50 mg/mL . The currest status of Diphenhydramine Hydrochloride drug is Active.

Drug Information:

Drug NDC: 55154-9363
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Diphenhydramine Hydrochloride
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Diphenhydramine Hydrochloride
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Cardinal Health 107, Llc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Injection, Solution
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:DIPHENHYDRAMINE HYDROCHLORIDE - 50 mg/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:INTRAMUSCULAR
INTRAVENOUS
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: ANDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 28 May, 2002
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 21 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: ANDA040466
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Cardinal Health 107, LLC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:1723740
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
UPC:0055154936354
UPC stands for Universal Product Code.
UNII:TC2D6JAD40
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Histamine H1 Receptor Antagonists [MoA]
Histamine-1 Receptor Antagonist [EPC]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
55154-9363-55 VIAL in 1 BAG (55154-9363-5) / 1 mL in 1 VIAL28 May, 2002N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Diphenhydramine hydrochloride diphenhydramine hydrochloride diphenhydramine hydrochloride diphenhydramine sodium hydroxide hydrochloric acid

Indications and Usage:

Indications and usage: diphenhydramine hydrochloride in the injectable form is effective in adults and pediatric patients, other than premature infants and neonates, for the following conditions when diphenhydramine hydrochloride in the oral form is impractical. antihistaminic for amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled, and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. motion sickness for active treatment of motion sickness. antiparkinsonism for use in parkinsonism, when oral therapy is impossible or contraindicated, as follows: parkinsonism in the elderly who are unable to tolerate more potent agents; mild cases of parkinsonism in other age groups, and in other cases of parkinsonism in combination with centrally acting anticholinergic agents.

Antihistaminic for amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled, and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated.

Motion sickness for active treatment of motion sickness.

Antiparkinsonism for use in parkinsonism, when oral therapy is impossible or contraindicated, as follows: parkinsonism in the elderly who are unable to tolerate more potent agents; mild cases of parkinsonism in other age groups, and in other cases of parkinsonism in combination with centrally acting anticholinergic agents.

Warnings:

Warnings: antihistamines should be used with considerable caution in patients with narrow-angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, or bladder-neck obstruction. local necrosis has been associated with the use of subcutaneous or intradermal use of intravenous diphenhydramine hydrochloride. use in pediatric patients in pediatric patients, especially, antihistamines in overdosage may cause hallucinations, convulsions, or death. as in adults, antihistamines may diminish mental alertness in pediatric patients. in the young pediatric patient, particularly, they may produce excitation. use in the elderly (approximately 60 years or older) antihistamines are more likely to cause dizziness, sedation, and hypotension in elderly patients.

Use in pediatric patients in pediatric patients, especially, antihistamines in overdosage may cause hallucinations, convulsions, or death. as in adults, antihistamines may diminish mental alertness in pediatric patients. in the young pediatric patient, particularly, they may produce excitation.

Use in the elderly (approximately 60 years or older) antihistamines are more likely to cause dizziness, sedation, and hypotension in elderly patients.

Dosage and Administration:

Dosage and administration: this product is for intravenous or intramuscular administration only. diphenhydramine hydrochloride in the injectable form is indicated when the oral form is impractical. parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. dosage should be individualized according to the needs and the response of the patient. pediatric patients, other than premature infants and neonates: 5 mg/kg/24 hr or 150 mg/m 2 /24 hr. maximum daily dosage is 300 mg. divide into four doses, administered intravenously at a rate generally not exceeding 25 mg/min, or deep intramuscularly. adults: 10 to 50 mg intravenously at a rate generally not exceeding 25 mg/min, or deep intramuscularly, 100 mg if required; maximum daily dosage is 400 mg.

Contraindications:

Contraindications: use in neonates or premature infants this drug should not be used in neonates or premature infants. use in nursing mothers because of the higher risk of antihistamines for infants generally, and for neonates and prematures in particular, antihistamine therapy is contraindicated in nursing mothers. use as a local anesthetic because of the risk of local necrosis, this drug should not be used as a local anesthetic. antihistamines are also contraindicated in the following conditions: hypersensitivity to diphenhydramine hydrochloride and other antihistamines of similar chemical structure.

Use in neonates or premature infants this drug should not be used in neonates or premature infants.

Use in nursing mothers because of the higher risk of antihistamines for infants generally, and for neonates and prematures in particular, antihistamine therapy is contraindicated in nursing mothers.

Use as a local anesthetic because of the risk of local necrosis, this drug should not be used as a local anesthetic. antihistamines are also contraindicated in the following conditions: hypersensitivity to diphenhydramine hydrochloride and other antihistamines of similar chemical structure.

Adverse Reactions:

Adverse reactions: the most frequent adverse reactions are underscored. 1. general: urticaria, drug rash, anaphylactic shock, photosensitivity, excessive perspiration, chills, dryness of mouth, nose and throat. 2. cardiovascular system: hypotension, headache, palpitations, tachycardia, extrasystoles. 3. hematologic system: hemolytic anemia, thrombocytopenia, agranulocytosis. 4. nervous system: sedation , sleepiness , dizziness , disturbed coordination , fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paresthesia, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, neuritis, convulsions. 5. gi system: epigastric distress , anorexia, nausea, vomiting, diarrhea, constipation. 6. gu system: urinary frequency, difficult urination, urinary retention, early menses. 7. respiratory system: thickening of bronchial secretions , tightness of chest or throat and wheezing, nasal stuffiness.

Overdosage:

Overdosage: antihistamine overdosage reactions may vary from central nervous system depression to stimulation. stimulation is particularly likely in pediatric patients. atropine-like signs and symptoms; dry mouth; fixed, dilated pupils; flushing; and gastrointestinal symptoms may also occur. stimulants should not be used. vasopressors may be used to treat hypotension.

Description:

Description: diphenhydramine hydrochloride is an antihistamine drug having the chemical name 2-(diphenylmethoxy)-n,n-dimethylethylamine hydrochloride. it occurs as a white, crystalline powder, is freely soluble in water and alcohol. the structural formula is as follows: c 17 h 21 no•hcl m.w. 291.82 diphenhydramine hydrochloride in the parenteral form is a sterile, pyrogen-free solution available in a concentration of 50 mg of diphenhydramine hydrochloride per ml. ph 4.0 to 6.5; sodium hydroxide and/or hydrochloric acid added, if needed, for ph adjustment. structural formula

Clinical Pharmacology:

Clinical pharmacology: diphenhydramine hydrochloride is an antihistamine with anticholinergic (drying) and sedative side effects. antihistamines appear to compete with histamine for cell receptor sites on effector cells. diphenhydramine hydrochloride in the injectable form has a rapid onset of action. diphenhydramine hydrochloride is widely distributed throughout the body, including the cns. a portion of the drug is excreted unchanged in the urine, while the rest is metabolized via the liver. detailed information on the pharmacokinetics of diphenhydramine hydrochloride injection is not available.

How Supplied:

How supplied: diphenhydramine hydrochloride injection, usp in parenteral form is supplied as: ndc no. strength volume 55154-9363-5 50 mg/ml 1 ml fill in a 2 ml vial. it is supplied as a sterile, pyrogen-free solution containing 50 mg diphenhydramine hydrochloride in each milliliter of solution. the container closure is not made with natural rubber latex. store at 20° to 25°c (68° to 77°f) [see usp controlled room temperature]. protect from light. keep from freezing.

Package Label Principal Display Panel:

Package/label display panel diphenhydramine hydrochloride injection, usp 50 mg/ml high potency 5 x 1 ml in a 2 ml single dose vials bag label


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.